Kyverna Therapeutics (KYTX) Competitors $3.92 -0.23 (-5.54%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.92 0.00 (0.00%) As of 09/12/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYTX vs. MAZE, RZLT, RLAY, IMTX, MRVI, KROS, TERN, TRML, SIGA, and PVLAShould you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Maze Therapeutics (MAZE), Rezolute (RZLT), Relay Therapeutics (RLAY), Immatics (IMTX), Maravai LifeSciences (MRVI), Keros Therapeutics (KROS), Terns Pharmaceuticals (TERN), Tourmaline Bio (TRML), Siga Technologies (SIGA), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. Kyverna Therapeutics vs. Its Competitors Maze Therapeutics Rezolute Relay Therapeutics Immatics Maravai LifeSciences Keros Therapeutics Terns Pharmaceuticals Tourmaline Bio Siga Technologies Palvella Therapeutics Maze Therapeutics (NASDAQ:MAZE) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Is MAZE or KYTX more profitable? Maze Therapeutics' return on equity of 0.00% beat Kyverna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Maze TherapeuticsN/A N/A N/A Kyverna Therapeutics N/A -64.98%-56.17% Do analysts recommend MAZE or KYTX? Maze Therapeutics currently has a consensus target price of $30.17, suggesting a potential upside of 29.47%. Kyverna Therapeutics has a consensus target price of $16.60, suggesting a potential upside of 323.47%. Given Kyverna Therapeutics' higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Kyverna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do institutionals & insiders hold more shares of MAZE or KYTX? 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 22.0% of Kyverna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor MAZE or KYTX? In the previous week, Maze Therapeutics had 20 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 22 mentions for Maze Therapeutics and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.83 beat Maze Therapeutics' score of 0.97 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has stronger valuation and earnings, MAZE or KYTX? Maze Therapeutics has higher revenue and earnings than Kyverna Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaze Therapeutics$167.50M6.10$52.23MN/AN/AKyverna TherapeuticsN/AN/A-$127.48M-$3.68-1.07 SummaryMaze Therapeutics beats Kyverna Therapeutics on 7 of the 11 factors compared between the two stocks. Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYTX vs. The Competition Export to ExcelMetricKyverna TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$179.47M$3.20B$5.87B$10.13BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-1.0721.1774.5225.93Price / SalesN/A436.80537.17192.28Price / CashN/A46.6837.5660.44Price / Book0.649.6112.166.29Net Income-$127.48M-$53.29M$3.28B$270.77M7 Day Performance-0.51%0.28%0.87%3.88%1 Month Performance12.97%5.73%4.96%4.88%1 Year Performance-45.56%10.52%60.74%26.01% Kyverna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYTXKyverna Therapeutics3.2124 of 5 stars$3.92-5.5%$16.60+323.5%-43.9%$179.47MN/A-1.0796Positive NewsMAZEMaze TherapeuticsN/A$14.49+1.5%$25.60+76.7%N/A$635.40M$167.50M0.00121Trending NewsAnalyst ForecastRZLTRezolute2.7547 of 5 stars$7.12-1.4%$12.50+75.6%+47.3%$619.41MN/A-6.1940News CoveragePositive NewsUpcoming EarningsRLAYRelay Therapeutics2.9218 of 5 stars$3.59-2.7%$17.08+375.9%-47.6%$618.96M$10.01M-1.84330IMTXImmatics2.929 of 5 stars$5.09-3.6%$14.67+188.1%-53.3%$618.69M$168.65M-7.83260Positive NewsHigh Trading VolumeMRVIMaravai LifeSciences3.5493 of 5 stars$2.42+1.7%$5.22+115.7%-69.0%$617.98M$259.18M-1.78610Positive NewsKROSKeros Therapeutics3.4599 of 5 stars$15.21-0.3%$30.00+97.2%-72.2%$617.76M$3.55M49.07100Positive NewsTERNTerns Pharmaceuticals4.0063 of 5 stars$6.96-1.6%$15.63+124.5%-24.0%$609.08MN/A-6.6940Positive NewsTRMLTourmaline Bio0.9053 of 5 stars$23.40+1.6%$50.14+114.3%+167.3%$601.20MN/A-6.8244Trending NewsAnalyst DowngradeSIGASiga Technologies1.6195 of 5 stars$8.39+2.2%N/A+13.3%$600.77M$138.72M7.4240Positive NewsPVLAPalvella Therapeutics1.8861 of 5 stars$54.15+5.6%$58.50+8.0%N/A$598.88M$42.81M-4.48N/AAnalyst Forecast Related Companies and Tools Related Companies MAZE Alternatives RZLT Alternatives RLAY Alternatives IMTX Alternatives MRVI Alternatives KROS Alternatives TERN Alternatives TRML Alternatives SIGA Alternatives PVLA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYTX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KYTX Stock Alerts